stoxline Quote Chart Rank Option Currency Glossary
  
Cognition Therapeutics, Inc. (CGTX)
0.5901  0 (0.02%)    02-14 16:00
Open: 0.585
High: 0.6373
Volume: 379,517
  
Pre. Close: 0.59
Low: 0.5801
Market Cap: 25(M)
Technical analysis
2025-02-14 4:47:01 PM
Short term     
Mid term     
Targets 6-month :  0.84 1-year :  0.95
Resists First :  0.72 Second :  0.81
Pivot price 0.65
Supports First :  0.57 Second :  0.47
MAs MA(5) :  0.59 MA(20) :  0.67
MA(100) :  0.55 MA(250) :  1.19
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  10.2 D(3) :  9
RSI RSI(14): 39.6
52-week High :  2.95 Low :  0.34
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CGTX ] has closed above bottom band by 24.0%. Bollinger Bands are 11% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.64 - 0.64 0.64 - 0.65
Low: 0.57 - 0.58 0.58 - 0.58
Close: 0.58 - 0.59 0.59 - 0.6
Company Description

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Headline News

Thu, 30 Jan 2025
CGTX - Cognition Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Wed, 08 Jan 2025
Cognition Therapeutics Advances DLB Treatment After Positive Phase 2 Results, CEO to Present at JPM Week - StockTitan

Wed, 08 Jan 2025
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - GlobeNewswire

Fri, 20 Dec 2024
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data - Yahoo Finance

Wed, 18 Dec 2024
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire

Thu, 28 Nov 2024
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 42 (M)
Shares Float 34 (M)
Held by Insiders 0.5 (%)
Held by Institutions 24.5 (%)
Shares Short 816 (K)
Shares Short P.Month 531 (K)
Stock Financials
EPS -0.96
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.75
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -93.7 %
Return on Equity (ttm) -108.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.42
Qtrly Earnings Growth 0 %
Operating Cash Flow -23 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -0.62
PEG Ratio 0
Price to Book value 0.77
Price to Sales 0
Price to Cash Flow -1.08
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android